These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15930018)

  • 21. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
    Toussaint ND; Lau KK; Polkinghorne KR; Kerr PG
    Nephrology (Carlton); 2011 Mar; 16(3):290-8. PubMed ID: 21342323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.
    Sonikian MA; Pani IT; Iliopoulos AN; Koutala KG; Marioli SI; Vlassopoulos DA
    Ren Fail; 2005; 27(2):143-7. PubMed ID: 15807177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
    Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
    Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
    Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
    Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
    Yokoyama T; Onodera Y; Mano T
    Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular calcification in patients with end-stage renal disease.
    Floege J; Ketteler M
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V59-66. PubMed ID: 15284362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
    Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
    Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different routes bridging calcium in Japanese hemodialysis patients.
    Hamano T; Fujii N; Ito T; Imai E
    Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN;
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium.
    Spasovski G; Gelev S; Masin-Spasovska J; Selim G; Sikole A; Vanholder R
    Bone; 2007 Oct; 41(4):698-703. PubMed ID: 17643363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.
    Di Iorio B; Molony D; Bell C; Cucciniello E; Bellizzi V; Russo D; Bellasi A;
    Am J Kidney Dis; 2013 Oct; 62(4):771-8. PubMed ID: 23684755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.